Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2392)
All Articles published online
|
Nov 28, 2007 (publication date) through Apr 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Rodriguez J, Zarate R, Bandres E, Viudez A, Chopitea A, García-Foncillas J, Gil-Bazo I. Combining chemotherapy and targeted therapies in metastatic colorectal cancer. World J Gastroenterol 2007; 13(44): 5867-5876 [PMID: 17990352 DOI: 10.3748/wjg.v13.i44.5867] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i44/5867.htm |
| Number | Citing Articles |
| 1 |
Mahnoor Naseer Gondal, Rida Nasir Butt, Osama Shiraz Shah, Muhammad Umer Sultan, Ghulam Mustafa, Zainab Nasir, Risham Hussain, Huma Khawar, Romena Qazi, Muhammad Tariq, Amir Faisal, Safee Ullah Chaudhary. A Personalized Therapeutics Approach Using an In Silico Drosophila Patient Model Reveals Optimal Chemo- and Targeted Therapy Combinations for Colorectal Cancer. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.692592
|
| 2 |
Ricardo Lima Barros Costa. Review Article: Targeted Therapy: Comprehensive Review. American Journal of Hospice and Palliative Medicine® 2009; 26(2): 137 doi: 10.1177/1049909108330026
|
| 3 |
Yan Ding, Xiaobing Huang, Taiping Liu, Yong Fu, Zhangping Tan, Hong Zheng, Taoli Zhou, Jigang Dai, Wenyue Xu. The Plasmodium Circumsporozoite Protein, a Novel NF-κB Inhibitor, Suppresses the Growth of SW480. Pathology & Oncology Research 2012; 18(4): 895 doi: 10.1007/s12253-012-9519-7
|
| 4 |
Shayan Khozooei, Soundaram Veerappan, Irina Bonzheim, Stephan Singer, Cihan Gani, Mahmoud Toulany. Fisetin overcomes non-targetability of mutated KRAS induced YB-1 signaling in colorectal cancer cells and improves radiosensitivity by blocking repair of radiation-induced DNA double-strand breaks. Radiotherapy and Oncology 2023; 188: 109867 doi: 10.1016/j.radonc.2023.109867
|
| 5 |
Martin Benesch, Christian Urban. Bevacizumab for refractory solid tumors in pediatric patients. Pediatric Health 2008; 2(2): 147 doi: 10.2217/17455111.2.2.147
|
| 6 |
John W. Tumeh, Pareen J. Shenoy, Susan G. Moore, John Kauh, Christopher Flowers. A Markov Model Assessing the Effectiveness and Cost-Effectiveness of FOLFOX Compared With FOLFIRI for the Initial Treatment of Metastatic Colorectal Cancer. American Journal of Clinical Oncology 2009; 32(1): 49 doi: 10.1097/COC.0b013e31817c6a4d
|
| 7 |
Arundhati Jana, Nancy L. Krett, Grace Guzman, Ahmer Khalid, Ozkan Ozden, Jonas J. Staudacher, Jessica Bauer, Seung Hyun Baik, Timothy Carroll, Cemal Yazici, Barbara Jung. NFkB is essential for activin-induced colorectal cancer migration via upregulation of PI3K-MDM2 pathway. Oncotarget 2017; 8(23): 37377 doi: 10.18632/oncotarget.16343
|
| 8 |
Christine L.H. Snozek, Dennis J. O'Kane, Alicia Algeciras-Schimnich. Pharmacogenetics of Solid Tumors: Directed Therapy in Breast, Lung, and Colorectal Cancer. The Journal of Molecular Diagnostics 2009; 11(5): 381 doi: 10.2353/jmoldx.2009.090003
|
| 9 |
Jesús García-Foncillas, Eduardo Díaz-Rubio. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clinical and Translational Oncology 2010; 12(8): 533 doi: 10.1007/s12094-010-0551-3
|
| 10 |
Daniel J. Freeman. Safety and Efficacy of Panitumumab in the Treatment of Metastatic Colorectal Cancer. Clinical Medicine. Therapeutics 2009; 1: CMT.S2039 doi: 10.4137/CMT.S2039
|
| 11 |
Arundhati Jana, Archita Das, Nancy L. Krett, Grace Guzman, Alexandra Thomas, Georgina Mancinelli, Jessica Bauer, Masuko Ushio-Fukai, Tohru Fukai, Barbara Jung, Salvatore V. Pizzo. Nuclear translocation of Atox1 potentiates activin A-induced cell migration and colony formation in colon cancer. PLOS ONE 2020; 15(1): e0227916 doi: 10.1371/journal.pone.0227916
|
| 12 |
Jeffrey S. Ross, Jorge Torres-Mora, Nikhil Wagle, Timothy A. Jennings, David M. Jones. Biomarker-Based Prediction of Response to Therapy for Colorectal Cancer. American Journal of Clinical Pathology 2010; 134(3): 478 doi: 10.1309/AJCP2Y8KTDPOAORH
|
| 13 |
John L. Marshall. Vascular Endothelial Growth Factor Plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?. Journal of Oncology 2009; 2009: 1 doi: 10.1155/2009/937305
|
| 14 |
Jeffrey S Ross. Biomarker-based selection of therapy for colorectal cancer. Biomarkers in Medicine 2011; 5(3): 319 doi: 10.2217/bmm.11.38
|
| 15 |
Alicia Algeciras-Schimnich, Dennis J. O'Kane, Christine L.H. Snozek. Pharmacogenomics of Tamoxifen and Irinotecan Therapies. Clinics in Laboratory Medicine 2008; 28(4): 553 doi: 10.1016/j.cll.2008.05.004
|
| 16 |
Ji-Kun Li, Liang Yu, Yun Shen, Li-Sheng Zhou, Yi-Cheng Wang, Jian-Hai Zhang. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells <italic>in vitro</italic>. World Journal of Gastroenterology 2008; 14(15): 2308-2313 doi: 10.3748/wjg.14.2308
|
| 17 |
Kei Sakamoto, Shin Maeda, Yohko Hikiba, Hayato Nakagawa, Yoku Hayakawa, Wataru Shibata, Ayako Yanai, Keiji Ogura, Masao Omata. Constitutive NF-κB Activation in Colorectal Carcinoma Plays a Key Role in Angiogenesis, Promoting Tumor Growth. Clinical Cancer Research 2009; 15(7): 2248 doi: 10.1158/1078-0432.CCR-08-1383
|
| 18 |
Béla Pikó. Panitumumab alkalmazása az áttétes vastag- és végbélrákos betegek kezelésében. Magyar Onkológia 2009; 53(2): 135 doi: 10.1556/MOnkol.53.2009.2.5
|
| 19 |
Kei Sakamoto, Shin Maeda. Targeting NF-κB for colorectal cancer. Expert Opinion on Therapeutic Targets 2010; 14(6): 593 doi: 10.1517/14728221003769903
|
| 20 |
XUEYING LU, HAIBO WEI, XIAOJIN ZHANG, WENXIN ZHENG, CHENG CHANG, JINYU GU. Rapamycin synergizes with low-dose oxaliplatin in the HCT116 colon cancer cell line by inducing enhanced apoptosis. Oncology Letters 2011; 2(4): 643 doi: 10.3892/ol.2011.299
|